SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta-analysis

Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism

(2016) François Briand et al.   DIABETES

Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials

(2016) Dandan Li et al.   DIABETES OBESITY & METABOLISM

DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects

(2016) André J. Scheen   Expert Opinion on Drug Metabolism & Toxicology

Sodium-glucose cotransporter-2 inhibitors and genital and urinary tract infections in type 2 diabetes

(2016) Richard F. Arakaki   POSTGRADUATE MEDICINE

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence

(2014) A.J. Scheen et al.   DIABETES & METABOLISM

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2014) Silvio E. Inzucchi et al.   DIABETES CARE

Genital and urinary tract infections in diabetes: Impact of pharmacologically-induced glucosuria

(2014) Suzanne Geerlings et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production

(2014) Aurora Merovci et al.   JOURNAL OF CLINICAL INVESTIGATION

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

(2014) Ele Ferrannini et al.   JOURNAL OF CLINICAL INVESTIGATION

Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials

(2013) Maximilian von Eynatten et al.   Cardiovascular Diabetology